A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis

Contact:

NCT Number:

Protocol:

AAAT8104

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

The purpose of this study is to: • to determine the optimal dose of oral CGT9486 in patients with Advanced Systemic Mastocytosis (AdvSM). • to determine the efficacy of CGT9486 at the selected optimal dose in patients with Advanced Systemic Mastocytosis (AdvSM).

Are you Eligible? (Inclusion Criteria)

  • Age ≥18 years of age
  • Have a form of Advanced Systemic Mastocytosis (including Aggressive Systemic Mastocytosis, Advanced Systemic Mastocytosis with an Associated Hematologic Neoplasm, or Mast Cell Leukemia).
  • Measurable disease, per Diagnosis of Systemic Mastocytosis (SM) criteria.

Specialty Area(s)

Leukemia

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032